Per Wold-Olsen
Retired President,
Human Health Intercontinental Division, Merck & Co., Inc.

Mr. Wold-Olsen joined Gilead’s Board of Directors in January 2010 after serving as the Chair of the company’s Health Policy Advisory Board since 2007. From 2005 to 2006, Mr. Wold-Olsen served as President of the Human Health Intercontinental Division of Merck & Co., Inc., a leading global pharmaceutical company. From 1997 until 2005, he served as President of Human Health Europe, Middle East/Africa and Worldwide Human Health Marketing for Merck & Co.,Inc. Mr. Wold-Olsen is currently Chairman of the Board of GN Store Nord A/S. He also serves as a director of Novo A/S. Mr. Wold-Olsen is the Chair of the Board of the Medicines for Malaria Venture (MMV), a non-profit initiative dedicated to the discovery, development and delivery of new medicines for the treatment of malaria. Mr. Wold-Olsen previously served as a director of PharmaNet Development Group, Inc., Royal Duch Numico, Exicon A/S and H. Lundbeck A/S. In his more than 30-year career at Merck, Mr. Wold-Olsen held various leadership positions within the company with responsibility for 15,000 employees in more than 100 markets in Europe, Eastern Europe, Middle East/Africa, India, Latin America and Canada. Mr. Wold-Olsen played an integral part in Merck’s significant growth in the European market, led a reassessment of Merck’s strategy in India after the company’s 20-year absence in the country, provided leadership to the company’s corporate responsibility initiatives as member of the Merck Company Foundation Oversight Committee, and helped direct the company’s HIV/AIDS initiatives in emerging markets and the developing world. A Principal Board member of the Accelerating Access Initiative (AAI), Mr. Wold-Olsen helped spearhead Merck’s involvement with the coalition, which was responsible for supplying HIV treatment to more than 700,000 patients in the developing world from 2000 to 2005. In addition to AAI, Mr. Wold-Olsen led several of Merck’s HIV/AIDS access initiatives, including a partnership among the Merck Company Foundation, Bill & Melinda Gates Foundation and the Government of Botswana to address HIV in the country, as well as a partnership with the Government of Romania aimed at eradicating pediatric AIDS and providing universal access to antiretrovirals.

Mr. Wold-Olsen is recognized worldwide for his leadership in pharmaceutical marketing and policy issues, and has written articles on the topics for publications including Wall Street Journal Europe, Eurohealth and SCRIP.

He is a current Chair of the Board of Medicines for Malaria Venture, Chairman of the Board of a top 20 listed Global Danish based Company, active with several biotech Boards and a past Chair and past member of the Europe Committee of Pharmaceutical Research and Manufacturers of America (PhRMA). Mr. Wold-Olsen received MBAs in Economics/Administration from the Norwegian School of Management and in Management/Marketing from the University of Wisconsin.

NASDAQ (US Dollar)
 Stock is Up 0.31 (0.43%)
Data as of 11/22/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh Quote
Recent Webcasts
Gilead Sciences at Morgan Stanley Global Healthcare Conference

September 11, 2017 9:55 a.m. ET
Gilead Sciences at Citi’s 12th Annual Biotech Conference

September 06, 2017 11:00 a.m. ET
Gilead Sciences Business Update

August 28, 2017 8:00 a.m. ET